Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab mechanism-of-action study in spondyloarthritis synovitis
NL-OMON41538Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in spondyloarthritis (SpA) and ankylosing spondylitis (AS), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in synovial cellular and molecular pathways at week 12, Global synovial histology and inflammatory infiltration and 4 more. Started Feb 2014; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
spondyloarthritis (SpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON41538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41538.